Evidence map›Paper›PMID 26001296›Full record

ArticleOncotarget2015

A six gene expression signature defines aggressive subtypes and predicts outcome in childhood and adult acute lymphoblastic leukemia.

Jin Wang, Jian-Qing Mi, Alexandra Debernardi, Anne-Laure Vitte, Anouk Emadali, Julia A Meyer, Konstantina Charmpi, Bernard Ycart, Mary B Callanan, William L Carroll and 2 more

Registry-linked trialOpen access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03436069 (Identification de Nouveaux Marqueurs Pronostiques Des Cancers du Sein), which is not on this map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03436069 recruitingnot on this map

Identification de Nouveaux Marqueurs Pronostiques Des Cancers du Sein

TypeobservationalSponsorUniversity Hospital, GrenobleRan2011 to 2033Enrolled1,500ConditionsBreast CancerArmsConventional treatment protocols of breast cancer
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Microtubule Minus-End Binding Proteins in Cancer: Advances.Diagnostics (Basel, Switzerland) · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Systematic Analysis of FASTK Gene Family Alterations in Cancer.International journal of molecular sciences · 2021
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Jin WangState Key Laboratory for Medical Genomics and Department of Hematology, Shanghai Institute of Hematology, Collaborative Innovation Center of Systems Biomedicine, Pôle Sino-Français des Sciences du Vivant et Genomique, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jian-Qing MiState Key Laboratory for Medical Genomics and Department of Hematology, Shanghai Institute of Hematology, Collaborative Innovation Center of Systems Biomedicine, Pôle Sino-Français des Sciences du Vivant et Genomique, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Alexandra DebernardiINSERM, Université Grenoble Alpes, Institut Albert Bonniot, Grenoble, France.
Anne-Laure VitteINSERM, Université Grenoble Alpes, Institut Albert Bonniot, Grenoble, France.
Anouk EmadaliINSERM, Université Grenoble Alpes, Institut Albert Bonniot, Grenoble, France.
Julia A MeyerNYU Cancer Institute, NYU Langone Medical Center, New York, USA.
Konstantina CharmpiLaboratoire Jean Kuntzmann, CNRS, Grenoble, France.
Bernard YcartLaboratoire Jean Kuntzmann, CNRS, Grenoble, France.
Mary B CallananINSERM, Université Grenoble Alpes, Institut Albert Bonniot, Grenoble, France.
William L CarrollNYU Cancer Institute, NYU Langone Medical Center, New York, USA.
Saadi KhochbinINSERM, Université Grenoble Alpes, Institut Albert Bonniot, Grenoble, France.
Sophie RousseauxINSERM, Université Grenoble Alpes, Institut Albert Bonniot, Grenoble, France.
Université Grenoble Alpes · FRCentre National de la Recherche Scientifique · FRInserm · FRNYU Langone Health · USInstitut pour l'avancée des biosciences · FRShanghai Jiao Tong University · CN

Funding

Drug Resistant Pathways in Relapsed Acute Lymphoblastic Leukemia(ALL)R01CA140729 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L. · 2010 to 2020
$4.8M
NCI NIH HHS R01 CA140729
6 · The paper itself

Abstract

Abnormal gene expression in cancer represents an under-explored source of cancer markers and therapeutic targets. In order to identify gene expression signatures associated with survival in acute lymphoblastic leukemia (ALL), a strategy was designed to search for aberrant gene activity, which consists of applying several filters to transcriptomic datasets from two pediatric ALL studies. Six genes whose expression in leukemic blasts was associated with prognosis were identified:three genes predicting poor prognosis (AK022211, FASTKD1 and STARD4) and three genes associated with a favorable outcome (CAMSAP1, PCGF6 and SH3RF3). Combining the expression of these 6 genes could successfully predict prognosis not only in the two discovery pediatric ALL studies, but also in two independent validation cohorts of adult patients, one from a publicly available study and one consisting of 62 newly recruited Chinese patients. Moreover, our data demonstrate that our six gene based test is particularly efficient in stratifying MLL or BCR.ABL negative patients. Finally, common biological traits characterizing aggressive forms of ALL in both children and adults were found, including features of dormant hematopoietic stem cells, suggesting new therapeutic strategies.

Indexed as

AdultAsian PeopleBiomarkers, TumorCell DifferentiationChildChinaFemaleFusion Proteins, bcr-ablGene Expression ProfilingHumansMaleMembrane Transport ProteinsMicrotubule-Associated ProteinsPolycomb Repressive Complex 1Precision MedicinePrecursor Cell Lymphoblastic Leukemia-LymphomaBiomarkers, TumorCAMSAP1 protein, humanFASTK protein, humanFusion Proteins, bcr-ablMembrane Transport ProteinsMicrotubule-Associated ProteinsPCGF6 protein, humanPolycomb Repressive Complex 1Protein Serine-Threonine KinasesSTARD4 protein, humancancercancer stem cellsminimum residual diseasepersonalized medicinerisk stratification

Identifiers

PMID26001296
PMCPMC4599287
OpenAlexW1498287218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.